Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination—Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation

<div><p>The dietary supplement, trans-resveratrol and hesperetin combination (tRES-HESP), induces expression of glyoxalase 1, countering the accumulation of reactive dicarbonyl glycating agent, methylglyoxal (MG), in overweight and obese subjects. tRES-HESP produced reversal of insulin r...

Full description

Saved in:
Bibliographic Details
Main Author: Naila Rabbani (291722) (author)
Other Authors: Mingzhan Xue (3607649) (author), Martin O. Weickert (10930980) (author), Paul J. Thornalley (291723) (author)
Published: 2021
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1864513516781699072
author Naila Rabbani (291722)
author2 Mingzhan Xue (3607649)
Martin O. Weickert (10930980)
Paul J. Thornalley (291723)
author2_role author
author
author
author_facet Naila Rabbani (291722)
Mingzhan Xue (3607649)
Martin O. Weickert (10930980)
Paul J. Thornalley (291723)
author_role author
dc.creator.none.fl_str_mv Naila Rabbani (291722)
Mingzhan Xue (3607649)
Martin O. Weickert (10930980)
Paul J. Thornalley (291723)
dc.date.none.fl_str_mv 2021-07-11T03:00:00Z
dc.identifier.none.fl_str_mv 10.3390/nu13072374
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Reversal_of_Insulin_Resistance_in_Overweight_and_Obese_Subjects_by_trans-Resveratrol_and_Hesperetin_Combination_Link_to_Dysglycemia_Blood_Pressure_Dyslipidemia_and_Low-Grade_Inflammation/25756452
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Medical biochemistry and metabolomics
Nutrition and dietetics
polyphenol
insulin resistance
methylglyoxal
obesity
glyoxalase
low-grade inflammation
dc.title.none.fl_str_mv Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination—Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <div><p>The dietary supplement, trans-resveratrol and hesperetin combination (tRES-HESP), induces expression of glyoxalase 1, countering the accumulation of reactive dicarbonyl glycating agent, methylglyoxal (MG), in overweight and obese subjects. tRES-HESP produced reversal of insulin resistance, improving dysglycemia and low-grade inflammation in a randomized, double-blind, placebo-controlled crossover study. Herein, we report further analysis of study variables. MG metabolism-related variables correlated with BMI, dysglycemia, vascular inflammation, blood pressure, and dyslipidemia. With tRES-HESP treatment, plasma MG correlated negatively with endothelial independent arterial dilatation (r = −0.48, p < 0.05) and negatively with peripheral blood mononuclear cell (PBMC) quinone reductase activity (r = −0.68, p < 0.05)—a marker of the activation status of transcription factor Nrf2. For change from baseline of PBMC gene expression with tRES-HESP treatment, Glo1 expression correlated negatively with change in the oral glucose tolerance test area-under-the-curve plasma glucose (ΔAUGg) (r = −0.56, p < 0.05) and thioredoxin interacting protein (TXNIP) correlated positively with ΔAUGg (r = 0.59, p < 0.05). Tumor necrosis factor-α (TNFα) correlated positively with change in fasting plasma glucose (r = 0.70, p < 0.001) and negatively with change in insulin sensitivity (r = −0.68, p < 0.01). These correlations were not present with placebo. tRES-HESP decreased low-grade inflammation, characterized by decreased expression of CCL2, COX-2, IL-8, and RAGE. Changes in CCL2, IL-8, and RAGE were intercorrelated and all correlated positively with changes in MLXIP, MAFF, MAFG, NCF1, and FTH1, and negatively with changes in HMOX1 and TKT; changes in IL-8 also correlated positively with change in COX-2. Total urinary excretion of tRES and HESP metabolites were strongly correlated. These findings suggest tRES-HESP counters MG accumulation and protein glycation, decreasing activation of the unfolded protein response and expression of TXNIP and TNFα, producing reversal of insulin resistance. tRES-HESP is suitable for further evaluation for treatment of insulin resistance and related disorders.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Nutrients<br> License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/nu13072374" target="_blank">https://dx.doi.org/10.3390/nu13072374</a></p>
eu_rights_str_mv openAccess
id Manara2_98629cda2654cb83fa7354f205112cc5
identifier_str_mv 10.3390/nu13072374
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/25756452
publishDate 2021
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination—Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade InflammationNaila Rabbani (291722)Mingzhan Xue (3607649)Martin O. Weickert (10930980)Paul J. Thornalley (291723)Biomedical and clinical sciencesMedical biochemistry and metabolomicsNutrition and dieteticspolyphenolinsulin resistancemethylglyoxalobesityglyoxalaselow-grade inflammation<div><p>The dietary supplement, trans-resveratrol and hesperetin combination (tRES-HESP), induces expression of glyoxalase 1, countering the accumulation of reactive dicarbonyl glycating agent, methylglyoxal (MG), in overweight and obese subjects. tRES-HESP produced reversal of insulin resistance, improving dysglycemia and low-grade inflammation in a randomized, double-blind, placebo-controlled crossover study. Herein, we report further analysis of study variables. MG metabolism-related variables correlated with BMI, dysglycemia, vascular inflammation, blood pressure, and dyslipidemia. With tRES-HESP treatment, plasma MG correlated negatively with endothelial independent arterial dilatation (r = −0.48, p < 0.05) and negatively with peripheral blood mononuclear cell (PBMC) quinone reductase activity (r = −0.68, p < 0.05)—a marker of the activation status of transcription factor Nrf2. For change from baseline of PBMC gene expression with tRES-HESP treatment, Glo1 expression correlated negatively with change in the oral glucose tolerance test area-under-the-curve plasma glucose (ΔAUGg) (r = −0.56, p < 0.05) and thioredoxin interacting protein (TXNIP) correlated positively with ΔAUGg (r = 0.59, p < 0.05). Tumor necrosis factor-α (TNFα) correlated positively with change in fasting plasma glucose (r = 0.70, p < 0.001) and negatively with change in insulin sensitivity (r = −0.68, p < 0.01). These correlations were not present with placebo. tRES-HESP decreased low-grade inflammation, characterized by decreased expression of CCL2, COX-2, IL-8, and RAGE. Changes in CCL2, IL-8, and RAGE were intercorrelated and all correlated positively with changes in MLXIP, MAFF, MAFG, NCF1, and FTH1, and negatively with changes in HMOX1 and TKT; changes in IL-8 also correlated positively with change in COX-2. Total urinary excretion of tRES and HESP metabolites were strongly correlated. These findings suggest tRES-HESP counters MG accumulation and protein glycation, decreasing activation of the unfolded protein response and expression of TXNIP and TNFα, producing reversal of insulin resistance. tRES-HESP is suitable for further evaluation for treatment of insulin resistance and related disorders.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Nutrients<br> License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/nu13072374" target="_blank">https://dx.doi.org/10.3390/nu13072374</a></p>2021-07-11T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3390/nu13072374https://figshare.com/articles/journal_contribution/Reversal_of_Insulin_Resistance_in_Overweight_and_Obese_Subjects_by_trans-Resveratrol_and_Hesperetin_Combination_Link_to_Dysglycemia_Blood_Pressure_Dyslipidemia_and_Low-Grade_Inflammation/25756452CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/257564522021-07-11T03:00:00Z
spellingShingle Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination—Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation
Naila Rabbani (291722)
Biomedical and clinical sciences
Medical biochemistry and metabolomics
Nutrition and dietetics
polyphenol
insulin resistance
methylglyoxal
obesity
glyoxalase
low-grade inflammation
status_str publishedVersion
title Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination—Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation
title_full Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination—Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation
title_fullStr Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination—Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation
title_full_unstemmed Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination—Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation
title_short Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination—Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation
title_sort Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination—Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation
topic Biomedical and clinical sciences
Medical biochemistry and metabolomics
Nutrition and dietetics
polyphenol
insulin resistance
methylglyoxal
obesity
glyoxalase
low-grade inflammation